tween 3,090 and 4,860 ng/mL (2.5 to 4 Mmol/L), a significant increase in T101 RTA-IT-mediated cytotoxicity was observed ranging from 31 % to 60%. Neither CsA nor SDZ PSC 833 affected the rate of RTA-IT binding, internalization. intracellular trafficking, or degradation. Analysis of internalized T l O l RTA-IT molecules showed that these were essentially intact, which suggests that these enhancers may act only on a small population of RTA-ITS that escapes present investigational techniques. In conclusion, because the concentrations used are clinically achievable, CS appear to be promising agents for in vivo enhancement 0 1994 by The American Society of Hematology.
of RTA-ITS.
of RTA-ITS." Therefore, although these conjugates show stringent specific cytotoxicity, their clinical potential depend on ways of increasing their cytotoxic activity.
Potentiation of RTA-ITS, including TI01 RTA-IT, cytotoxicity has been achieved in vitro with the use of agents such as carboxylic ionophore^,'^^'^ lysosomotropic and calcium a n t a g~n i s t s .~~'~~'~"~ Some of these enhancers can be used ex vivo such as in bone marrow (BM) purging in humans,6 but most of them are ill-suited for in vivo use where the major obstacles are either their toxicity or short half-life after intravenous a d m i n i s t r a t i~n . '~~'~ Recent studies have suggested that cyclosporin A (CsA) increases the efficacy/toxicity of certain R T A -I T S .~~,~' Therefore, we evaluated the potential RTA-IT enhancement effect of CsA and its nonimmunosuppressive analog, SDZ PSC 883. Both CsA and SDZ PSC 833 were found to be both potent and specific enhancers of TI01 and TlOl F(ab)z RTA-IT in vitro. We also investigated the impact of these RTA-IT enhancers on the rate of TI0 1 RTA-IT intoxication, binding, internalization, intracellular degradation, and subcellular localization.
Hanover, NJ). These were dissolved in absolute ethanol at 1 mmol/ L and stored at -20°C. All other reagents were purchased from Sigma (St Louis, MO).
Human plasma. Plasma samples were obtained from four patients enrolled in a phase l trial of highdose CsA for modulation of multidrug re~istance.~~ Samples were collected before and 2 hours after CsA infusion. CsA levels were measured using a nonspecific fluorescence-polarization immunoassay that cross-reacts with both CsA and metabolites (TDX; Abbott Laboratories, North Chicago, IL) and found to be between 3,090 and 4,860 ng/mL.
Protein-synthesis inhibition assay. RTA-IT efficacy was evaluated by the inhibition of [3H]-Leucine incorporation as described previo~sly.~ Briefly, I X IO6 cells/mL in complete medium were treated during 18 hours at 37°C with various concentrations of toxin or RTA-IT and, when specified, in the presence of CS.
[3H]-leucine (specific activity, 150 Ci/mmol; 1 pCi/IOO-pL well; Amersham, Arlington Heights, IL) was added 6 hours before the end of treatment. Washed cells were harvested on filter paper (Cambridge Technology, Inc, Watertown, MA) and radioactivity was counted. Results of triplicate experiments are expressed as the percentage of control (cells not treated by toxin or RTA-IT). In experiments using human plasma, 2 X IO6 CEM 111 cells were pelleted and resuspended in 100% human plasma. After addition of 1 X IO-' mol/L TI01 RTA-IT, the final plasma concentration was 87%.
Iz5I labeling of TI01 RTA-IT. T 10 1 RTA-IT (50 pg) was labeled with 1 mCi of 1251 (Amersham) in the presence of chloramine T.25 After I minute of incubation, the reaction was stopped by the addition ofsodium metabisulfite followed by potassium iodide. Free 1251 was removed by chromatography on a phosphate-buffered PD-10 Sephadex G-25 M column (Pharmacia, Piscataway, NJ). The collected fractions that contained labeled protein were pooled and the radioactivity counted. The specific radioactivity of labeled TI01 RTA-IT was approximately 7.3 pCi/mg protein. Iodination did not modify the activity of TI01 RTA-IT (data not shown).
Rate of TI01 RTA-IT internalization in CEM 111 cells. The kinetics of T 10 I RTA-IT internalization was measured according to the previously described method.10,26 Briefly, CEM Ill cells were incubated for 1 hour at 4°C with 1251 labeled TI01 RTA-IT (at 10-fold the membrane-saturable concentration: 1 X IO-' mol/L) in complete medium. A negative control was performed by incubating the cells at 4°C with cold TI01 RTA-IT ( I X IO-' mol/L) 2 hours before addition of 1251-T101 RTA-IT. After three ice-cold washes with saline solution (removing excess '251-RTA-IT), cells (1 X lo6/ mL) were incubated at 37*C, with or without 4 pmol/L CsA, for various incubation times. At the end of these times, cells were pelleted by centrifugation and washed twice. The radioactivity of the collected supernatants, which represented non-cell-associated IZ5I-ligand, represented less than 10% of the total recovered radioactivity. Nonendocytosed cell-surface bound 1251-ligand was removed by treatment for 30 minutes at 4°C with 0.4% (wt/vol) Streptomyces griseus protease (Sigma). Protease treatment removed greater than 90% cell-surface bound radioactivity. Cells were again centrifuged and the radioactivity in the cell pellet and supernatant determined. From these determinations, the amount of TI01 RTA-IT endocytosed (Et) was calculated %Et = 100 X Pt/(Pt + St). Where Et = endocytosis at timet, Pt = counts/min in cell pellet at timet, and St = counts/min in supernatant (of protease-treated cells) at time t. Results are expressed as the percentage of total recovered radioactivity, which remained constant throughout the experiment. Radioactivity was determined with a gamma counter.
Analysis cf TI01 RTA-IT degradation in CEM III cells. After protease treatment, washed cells were lysed with 50 mmol/L Tris-HCI, 0.5% sodium dodecyl sulfate (SDS), pH 8. Intracellular nondegraded and degraded 1251-ligand were assessed by measuring the 10% trichloroacetic acid (TCA)-precipitable and soluble radioactivities, respectively.
PercoN gradient fractionation of organelles. The intracellular trafficking of 1251-T101 RTA-IT in CEM 111 cells was evaluated according to the previously described rneth~ds'.~' with slight modifications. Cells ( I X IO6) were incubated with 1 X IO-' mol/L '251-T 101 RTA-IT for 4 hours at 37°C with or without 4 pmol/L CsA or 4 pmol/L SDZ PSC 833. Cells were then washed twice in ice-cold phosphate-buffered saline and resuspended in 1 mL of cold buffer (250 mmol/L sucrose, I mmol/L EDTA, and IO mmol/L triethanolamine), and homogenized with 25 strokes of a Dounce homogenizer (Cole-Parmer Instrument CO, Niles, IL). After centrifugation at 250s for 10 minutes at 4°C to sediment nuclei and unbroken cells, the supernatant was recovered and carefully layered onto the surface of a tube containing 9 mL of 20% Percoll in cold buffer resting on a cushion of 0.5 mL 2.5 mol/L sucrose. Percoll gradients were generated by centrifugation at 20,OOOg for 90 minutes at 4°C. Fractions of 0.5 mL were collected from the top and the radioactivity counted.
Molecular-weight evaluation of internalized molecules. AAer 4
hours of incubation with 'Z51-TIOl RTA-IT at 37"C, cell-surface radioactivity was eluted from CEM 111 cells by treatment with S. griseus protease as described above. Analysis of the molecular weight of internalized 1251-T101 RTA-IT was performed according to the previously described method.' Cells (5 X IO') were solubilized for 30 minutes at 4°C in 3.5 mL of0.5% Nonidet-P40, 1% Triton X-1 0 0 , and 0.5% sodium deoxycholate containing protease inhibitors phenylmethylsulfonyl fluoride (IOOpg/mL), pepstatin A (1 wg/mL), leupeptin (2 pg/mL), and aprotinin (2 pg/mL). The lysates were obtained after centrifugation at 1 , OOOg and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on a 5% to 16% gradient gel?' Gels were autoradiographed at -70°C on Kodak X-OMAT AR film with Du Pont Cronex Lightning-Plus intensifying screens (Eastman Kodak, Rochester, NY) and analyzed by densitometry.
RESULTS
Enhancement of RTA-IT activity by CS. The ability of CsA and SDZ PSC 833 to enhance anti-CD5 RTA-ITS was evaluated by treating the human lymphoblastic T-cell line CEM I11 with various concentrations ofthe drugs and RTA-IT. Figure 1 illustrates the relatively weak cytotoxicity of TlOl RTA-IT compared with native ricin (>50,000-fold). Nevertheless, specificity and cytotoxicity are superior to ricin A-chain alone (about 10-fold). Coincubation of TlOl RTA-IT with either 4 pmol/L CsA or 4 pmol/L SDZ PSC 833 resulted in a significant increase in cytotoxicity (Table  1) . Enhancement of TlOl RTA-IT cytotoxicity was achieved within a narrow range of CS concentrations. At 1 pmol/L neither CsA nor SDZ PSC 833 had a significant effect on TI01 RTA-IT cytotoxicity. A significant effect of 20-to 30-fold was observed at 2 pmol/L for both CS, which further increased to greater than 100-fold at 4 pmol/L (a nontoxic concentration). However, CS toxicity reached about 20% at 6 pmol/L, which prevented their use at higher concentrations (data not shown).
T 10 1 F(ab), RTA-IT cytotoxicity on CEM 111 was about 10-fold more potent than its whole-fragment counterpart. This RTA-IT was also enhanced by CsA and SDZ PSC 833. At 2 pmol/L both CsA and SDZ PSC 833 had a limited effect of about twofold but this increased significantly to about IO-fold at 4 pmol/L. The enhancement effect of both CsA and SDZ PSC 833 was specific, because the toxicity of ricin A-chain alone and the control anti-CD1 9 RTA-IT was unaffected. Furthermore, neither TlOl RTA-IT or TI0 1 after which protein synthesis was measured. These were compared with the cytotoxicity of native ricin (----) .
Points are the means of at least three different experiments with SE no greater than 10%.
F(ab)2 RTA-IT showed any change in nonspecific toxicity on the irrelevant human Burkitt's lymphoma cell line, RAJ1 (data not shown).
Efect of Cs on the rate of protein-synthesis inhibition by anti-CD5 R TA-ITS. The inhibition by T 10 1 RTA-IT ( 1 X IO-' mol/L) of protein synthesis reached approximately 50% after 24 hours, whereas in the presence of 4 pmol/L CsA and 4 pmol/L SDZ PSC 833 it increased to 90% and 94%, respectively (P .025) (Fig 2A) . Compared with its whole-fragment counterpart, T 10 1 F(ab')z RTA-IT, reached 94% inhibition of protein synthesis within 24 hours, which was further increased to almost 99% with both 4 pmol/L CsA and 4 pmol/L SDZ PSC 833 (P -= .05) (Fig 2B) .
Enhancement o f TI01 RTA-IT in human plasma. The cytotoxicity of TI0 1 RTA-IT on CEM I11 cells was evaluated in a prospective experiment using human plasma (Fig  3) . TI0 I RTA-IT, 1 X lo-' mol/L, inhibited protein synthesis in the presence of four pre-CsA control-plasma samples by 43%, 52%, 6296, and 50%, respectively. In the presence ofpatient plasma obtained 2 hours post-CsA infusion24 Tl01 RTA-IT cytotoxicity increased to 6 l%, 77% 85%. and 77%, respectively.
Efects of CsA on internalization and degradation 0f"'I-TI01 RTA-IT. CEM 111 cells were incubated with a membrane-saturating concentration of 1251-T101 RTA-IT ( 1 X lo-' mol/L) for 1 hour at 4°C. After washing in ice-cold saline solution (removing excess 12%RTA-IT), CEM Ill cells were incubated at 3 7 T , with or without 4 pmol/L CsA. At specified times, cells were pelleted, membrane-bound labeled ligand was removed by a protease treatment, and the radioactivity of the pellet was determined. Figure 4 shows the slow internalization rate of TlOl RTA-IT in CEM 111 cells. Furthermore, treatment by 4 pmol/L CsA did not significantly modify the kinetics of internalization.
After protease treatment, CEM 111 cells were lysed and intracellular nondegraded and degraded "'1-ligand was branes in lower-density fractions and lysosomes in higherdensity fractions. Figure 6 shows that TI0 1 RTA-IT is distributed between fractions 6 and 19, representing densities between 1. l to 1.3 g/cm3. Treatment with 4 pmol/L CsA did not significantly modify the intracellular distribution of internalized T 10 1 RTA-IT (Fig 6) For enhanced, about IO-fold. In previous studies, we observed that other RTA-IT enhancers such as NH4Cl, monensin, and calcium antagonists, were less active on RTA-IT fragments than on their whole-Ig ~o u n t e r p a r t .~* '~* '~ We also observed that 4 pmol/L CsA increased the cytotoxicity of an anti-Thy 1.2 RTA-IT by 150-fold on the murine-leukemia cell line T2, and both 4 pmol/L CsA and 4 pmol/L SDZ PSC 833 increased the cytotoxicity of an anti-CD19 RTA-IT by 10-fold on the human Burkitt's lymphoma cell line RAJI (data not shown).
The RTA-IT enhancement effect of CS was specific because the toxicities of neither ricin A-chain alone nor the irrelevant anti-CD I9 RTA-IT (and an anti-HLA-DR RTA-IT, data not shown) were affected in CEM 111 cells. Furthermore, the nonspecific toxicity of both anti-CD5 RTA-ITS was also unaffected on the irrelevant human Burkitt's lymphoma cell line RAJI.
We extended our investigation by evaluating the cytotoxicity of T IO I RTA-IT in CEM 111 cells incubated in human plasma. We have previously shown that the activity of potent RTA-IT enhancers, such as monensin and perhexiline.
is inhibited by serum component^.^^ At the membrane saturating concentration of 1 X 1 0-8 mol/L, mean T IO 1 RTA-IT protein-synthesis inhibition in four plasma samples was about 50%, which was not significantly different from that observed in regular culture media. However, the cytotoxicity of the RTA-IT was increased to an average of 75% when CEM 111 were incubated in patient plasma after highdose CsA infusion.24 The CsA levels in the plasma were between 3,090 and 4,860 ng/mL (2.5 to 4 pmol/L) as assessed by the immunoassay, TDX. The fact that effective CsA levels can be achieved in vivo is a crucial observation. We have recently shown that highdose CsA can be administered with acceptable
Indeed, short-term infusion led to steady-state CsA levels up to 4 pmol/L, without long-term immunosuppressive consequences. Even though our in vitro experiments using patient's plasma were performed for 18 hours, the kinetics of cytotoxicity experiments, using the CEM 111 cell line, strongly indicated that shorter incubation times would also lead to significant enhancement of RTA-IT cytotoxicity. Moreover, prolonged exposure to both RTA-IT and CsA would be unnecessary because about 50% of the bound RTA-IT are already internalized in CEM 111 cells in little over 2 hours.
The mechanism by which drugs enhance RTA-IT cytotoxicity remains unclear. Certain agents such as the calcium antagonists perhexiline and SR33557 appear to act by blocking the intracellular degradation of RTA-ITS and profoundly modifying its However, lysosomotropic amines, such as NH4CI. and carboxylic ionophores, such as monensin, do not alter either degradation or intracellular trafficking of internalized RTA-ITs.~.' These agents do increase the kinetics of c y t o t o~i c i t y .~.~~'~~'~ T l0 l RTA-IT has a distinctive slow rate of cell intoxication,I2 and enhancers such as monensin and NH4Cl are able to increase the rate ofcell kill dramati~ally.~*'~ In our investigation, we found that both 4 pmol/L CsA and 4 pmoll L SDZ PSC 833 similarly increased the kinetics of protein synthesis inhibition of TI01 and TI01 F(ab')2 RTA-ITS.
Unlike the calcium antagonist, but much like monensin and NH4CI, CsA had no effect on membrane binding, internal- For personal use only. on October 30, 2017. by guest www.bloodjournal.org From that CLS substantially increased in patients who also received conventional CsA immunoprophylaxis may limit their combined use.*' However, CLS can be treated by glucocorticoid~,~~ and because CsA significantly enhances the rate of RTA-IT cytotoxicity, shorter RTA-IT treatment times may prove effective. CLS is a major side effect of IL-2 therapy,34 and may possibly be linked to the immunosuppressive activity of CsA. This would make the nonimmunosuppressive CsA analog, SDZ PSC 833, a more appropriate RTA-IT enhancer.
In conclusion, agents such as CS could significantly improve the clinical potential of RTA-ITS by enhancing their cytotoxicity. Although animal studies are required to confirm our observations, CsA and its nonimmunosuppressive analog, SDZ PSC 833, appear to be promising agents for in vivo RTA-IT enhancement. 
